CA2434387A1 - Marqueur susceptible d'etre selectionne pour des cellules et des tissus genetiquement modifies - Google Patents

Marqueur susceptible d'etre selectionne pour des cellules et des tissus genetiquement modifies Download PDF

Info

Publication number
CA2434387A1
CA2434387A1 CA002434387A CA2434387A CA2434387A1 CA 2434387 A1 CA2434387 A1 CA 2434387A1 CA 002434387 A CA002434387 A CA 002434387A CA 2434387 A CA2434387 A CA 2434387A CA 2434387 A1 CA2434387 A1 CA 2434387A1
Authority
CA
Canada
Prior art keywords
cells
gene
ires
expression vector
interest
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002434387A
Other languages
English (en)
Inventor
Jacques Galipeau
Nicoletta Eliopoulos
Richard L. Momparler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CENTRE FOR TRANSLATIONAL RESEARCH IN CANCER
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2434387A1 publication Critical patent/CA2434387A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/65—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression using markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

L'invention concerne un gène marqueur susceptible d'être sélectionné, un procédé de production de cellules génétiquement modifiées permettant l'expression d'un vecteur bicistronique et des applications en thérapie génique ex vivo. L'invention concerne également la sélection de cellules génétiquement modifiées provenant de population mixte, avant leur implantation in vivo. L'invention concerne en outre le gène humain de la cytidine déaminase (CD) tenant lieu de marqueur dominant susceptible d'être sélectionné ex vivo dans des cellules primaires à gène modifié avec des analogues de la cytosine nucléoside. Un rétrovecteur bicistronique comprenant la séquence codant la CD humaine et le gène rapporteur de la protéine fluorescente verte (GFP) améliorée est utilisé dans la transduction de cellules. L'invention concerne finalement l'introduction du gène CD dans les applications en thérapie cellulaire et génique pour la sélection dominante ex vivo de cellules génétiquement modifiées.
CA002434387A 2001-01-16 2002-01-16 Marqueur susceptible d'etre selectionne pour des cellules et des tissus genetiquement modifies Abandoned CA2434387A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26119001P 2001-01-16 2001-01-16
US60/261,190 2001-01-16
PCT/CA2002/000042 WO2002057472A1 (fr) 2001-01-16 2002-01-16 Marqueur susceptible d'etre selectionne pour des cellules et des tissus genetiquement modifies

Publications (1)

Publication Number Publication Date
CA2434387A1 true CA2434387A1 (fr) 2002-07-25

Family

ID=22992262

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002434387A Abandoned CA2434387A1 (fr) 2001-01-16 2002-01-16 Marqueur susceptible d'etre selectionne pour des cellules et des tissus genetiquement modifies

Country Status (3)

Country Link
EP (1) EP1352078A1 (fr)
CA (1) CA2434387A1 (fr)
WO (1) WO2002057472A1 (fr)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5770428A (en) * 1993-02-17 1998-06-23 Wisconsin Alumni Research Foundation Chimeric retrovial expression vectors and particles containing a simple retroviral long terminal repeat, BLV or HIV coding regions and cis-acting regulatory sequences, and an RNA translational enhancer with internal ribsome entry site
GB9524973D0 (en) * 1995-12-06 1996-02-07 Lynxvale Ltd Viral vectors
CA2325560A1 (fr) * 1998-04-14 1999-10-21 Chiron Corporation Technique sans clonage d'expression d'un gene interessant
US20020068711A1 (en) * 2000-03-14 2002-06-06 Pedersen Peter L. Arrest of proliferation of highly glycolytic tumors

Also Published As

Publication number Publication date
EP1352078A1 (fr) 2003-10-15
WO2002057472A1 (fr) 2002-07-25

Similar Documents

Publication Publication Date Title
Allay et al. Retroviral transduction and expression of the human alkyltransferase cDNA provides nitrosourea resistance to hematopoietic cells
JP6894236B2 (ja) 免疫刺激活性を有するレトロウイルスベクター
Paquin et al. Retrovector encoding a green fluorescent protein–herpes simplex virus thymidine kinase fusion protein serves as a versatile suicide/reporter for cell and gene therapy applications
Eliopoulos et al. Human cytidine deaminase as an ex vivo drug selectable marker in gene-modified primary bone marrow stromal cells
Barese et al. Contributions of gene marking to cell and gene therapies
Banerjee et al. Gene therapy utilizing drug resistance genes: a review
RU2185821C2 (ru) Трансдуцирующие цитохром р450 ретровирусные векторы
US20040115800A1 (en) Selectable marker for genetically engineered cells and tissues
Rettig et al. Transduction and selection of human T cells with novel CD34/thymidine kinase chimeric suicide genes for the treatment of graft-versus-host disease
Brenner et al. Gene transfer into human hemopoietic progenitor cells
METZ et al. Bicistronic and two-gene retroviral vectors for usingMDR1 as a selectable marker and a therapeutic gene
JPH11511651A (ja) 遺伝子治療に特に適した改良型レトロウイルスベクター
CA2434387A1 (fr) Marqueur susceptible d'etre selectionne pour des cellules et des tissus genetiquement modifies
US6485722B1 (en) Method for selective engraftment of drug-resistant hematopoietic stem cells
Gatlin et al. In vitro selection of lentivirus vector-transduced human CD34+ cells
Verfaillie et al. Gene therapy for chronic myelogenous leukemia
US6500421B1 (en) In vivo selection of primitive hematopoietic cells
CA2392941A1 (fr) Systeme inductible par medicament inductible et utilisation associee
CA2371216A1 (fr) Pseudotype de vecteur retroviral destine a la therapie genique du cancer
Lee et al. Cellular gene therapy
Brenner Gene transfer in haematological malignancy
Stripecke et al. Lentiviral and retroviral vector systems
Baum et al. New perspectives for cancer chemotherapy by genetic protection of haematopoietic cells
Benaim et al. Gene therapy in pediatric oncology
SCHMIDT-WOLF et al. Bone marrow and clinical gene therapy

Legal Events

Date Code Title Description
FZDE Discontinued